NKGEN BIOTECH INC(NKGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKGN NKGEN BIOTECH INC

Market Closed 06-07 16:00:00 EDT

1.45

+0.08

+5.84%

盘后1.37

-0.08-5.52%

19:33 EDT

High1.50	Low1.36	Vol122.03K
Open1.37	D1 Closing1.37	Amplitude10.22%
Mkt Cap36.09M	Tradable Cap17.00M	Total Shares24.89M
T/O174.39K	T/O Rate1.04%	Tradable Shares11.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NKGN","market":"US","secType":"STK","nameCN":"NKGEN BIOTECH INC","latestPrice":1.45,"timestamp":1717790400000,"preClose":1.37,"halted":0,"volume":122030,"hourTrading":{"tag":"盘后","latestPrice":1.37,"preClose":1.45,"latestTime":"19:33 EDT","volume":2207,"amount":3246.7822,"timestamp":1717803208570},"delay":0,"floatShares":11723800,"shares":24887799,"eps":-4.552847,"marketStatus":"Market Closed","change":0.08,"latestTime":"06-07 16:00:00 EDT","open":1.3696,"high":1.5,"low":1.36,"amount":174390.339528,"amplitude":0.10219,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.552847,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1718006400000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":1.37,"preHourTrading":{"tag":"盘前","latestPrice":1.3676,"preClose":1.37,"latestTime":"09:28 EDT","volume":7357,"amount":10051.4872717,"timestamp":1717766910687},"postHourTrading":{"tag":"盘后","latestPrice":1.37,"preClose":1.45,"latestTime":"19:33 EDT","volume":2207,"amount":3246.7822,"timestamp":1717803208570},"volumeRatio":0.8844304158765373,"overnightSupported":true},"requestUrl":"/m/hq/s/NKGN/tweets","defaultTab":"tweets","newsList":[{"id":"2440462414","title":"NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2440462414","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2440462414?lang=en_us&edition=fundamental","pubTime":"2024-06-03 20:05","pubTimestamp":1717416300,"startTime":"0","endTime":"0","summary":"SANTA ANA, Calif., June 03, 2024  -- NKGen Biotech, Inc.  , a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer  cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform as well as updated Phase 1 data on its use in solid tumors without lymphodepletion at the 6th Annual Allogeneic Cell Therapies Summit to be held in Boston, MA, from June 10-12, 2024.Protecting Patients by Removing Need for Lymphodepletion to Better Preserve Immune Function. SNK02 is a novel cell-based, donor-derived ex vivo expanded allogeneic NK cell immunotherapeutic drug candidate. NKGen Biotech, Inc. is developing SNK02 for the treatment of a broad range of cancers.Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B1ZPiw9UAepRzBSTCPQGgA--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/ff5a796e664612eddb6f6d9bc19bccdf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B1ZPiw9UAepRzBSTCPQGgA--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/ff5a796e664612eddb6f6d9bc19bccdf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkgen-biotech-present-updated-phase-120500408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKGNW","NKGN","SMMF","BK4211","BK4139"],"gpt_icon":0},{"id":"2437296719","title":"NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2437296719","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437296719?lang=en_us&edition=fundamental","pubTime":"2024-05-24 05:05","pubTimestamp":1716498300,"startTime":"0","endTime":"0","summary":"SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens with immune checkpoint inhibitors.In this Phase 1 trial, the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02.SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion.“Interim data from our Phase 1 clinical study utilizing our second NK cell therapy product, SNK02, demonstrated that the treatment was well-tolerated as a monotherapy in patients with solid tumors refractory to standard of care therapy,” said Paul Y. Song, MD, Chairman and CEO of NKGen. “We are particularly excited because SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tum","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B1ZPiw9UAepRzBSTCPQGgA--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/ff5a796e664612eddb6f6d9bc19bccdf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B1ZPiw9UAepRzBSTCPQGgA--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/ff5a796e664612eddb6f6d9bc19bccdf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkgen-biotech-publishes-phase-1-210500394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","BK4117","IE00B66KJ199.SGD","IE00B7SZL793.SGD","IP","AFG","BK4107","BK4585","BK4136","NKGN","NKGNW","BK4157","AEIS","BK4588","IE0031619046.USD"],"gpt_icon":0},{"id":"2437304480","title":"Sector Update: Health Care Stocks Softer Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2437304480","media":"MT Newswires","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437304480?lang=en_us&edition=fundamental","pubTime":"2024-05-21 03:58","pubTimestamp":1716235101,"startTime":"0","endTime":"0","summary":"Health care stocks were easing late Monday afternoon with the NYSE Health Care Index down 0.1%, and the Health Care Select Sector SPDR Fund  shedding 0.2%.In corporate news, Ensysce Biosciences  shares jumped 17% after the company said it renewed a collaboration with Quotient Sciences to undertake a study to examine and evaluate the full commercial dose range of pain relief drug PF614-MPAR.Lisata Therapeutics  shares rose 2% after it said Monday it has obtained a full pediatric waiver from the European Medicines Agency for investigational drug certepetide in pancreatic cancer.Hims & Hers Health  shares surged 27% after the company announced it's offering GLP-1 injections starting at $199 a month, using compounded versions of the active ingredient in weight loss drugs sold by Novo Nordisk  and Eli Lilly . Novo Nordisk shares added 0.8%, and Eli Lilly was up 1.7%.NKGen Biotech  soared 53% after it said Monday its safety review committee has cleared the company's expanded SNK01 cell thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sector-health-care-stocks-softer-195821835.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2602419157.SGD","LSTA","LU0079474960.USD","LU1551013425.SGD","NVO","NKGN","LU0198837287.USD","LU0061475181.USD","LU2491050071.SGD","IE00B2B36J28.USD","BK4585","LU0672654240.SGD","BK4007","LU0289739699.SGD","LU1551013342.USD","LU0097036916.USD","LU0058720904.USD","LU2468319806.SGD","LU1064131342.USD","LU2491049909.HKD","GB00BDT5M118.USD","BK4534","LU1712237335.SGD","LU1814569148.SGD","LU0114720955.EUR","IE00BJT1NW94.SGD","BK4588","LU0109391861.USD","LU0256863811.USD","BK4532","LU2237443549.SGD","LLY","LU2265009873.SGD","LU1267930730.SGD","LU2237443382.USD","XLV","LU0882574055.USD","IE0002141913.USD","IBB","IE0009355771.USD","ENSC","LU1988902786.USD","LU1023059063.AUD","LU0417517546.SGD","LU0122379950.USD","HIMS","LU0689472784.USD","LU2237438978.USD","BK4196","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2437488494","title":"SCPX, XTIA and CRVO among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2437488494","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437488494?lang=en_us&edition=fundamental","pubTime":"2024-05-21 01:12","pubTimestamp":1716225138,"startTime":"0","endTime":"0","summary":"Gainers: MultiMetaVerse Holdings Limited (MMV) +184%.GT Biopharma (GTBP) +164%.NKGen Biotech (NKGN) +54%.Bruush Oral Care (BRSH) +47%.Faraday Future Intelligent Electric (FFIE) +45%.Scorpius Holdings (SCPX) +37%.Pineapple Energy (PEGY) +36%.Cheetah Mobile (CMCM) +34%.Hims & Hers Health (HIMS) +32%.Serina Therapeutics (SER) +29%.Losers: Mmtec (MTC) -81%.Cheetah Net Supply Chain Service (CTNT) -60%.FLJ Group Ltd (FLJ) -44%.Fangdd Network Group Ltd ADR (DUO) -32%.XTI Aerospace Inc. (XTIA) -23%.CervoMed Inc (CRVO) -20%.Blue Star Foods Corp (BSFC) -20%.iPower (IPW) -19%.Lucy Scientific Discovery (LSDI) -17%.Digital Brands Group (DBGI) -17%.","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108460-scpx-xtia-and-crvo-among-mid-day-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4122","BK4096","CMCM","DBGI","SER","BK4196","BK4094","DUO","MTC","BK4023","BK4099","BK4509","CTNT","MMV","PEGY","NKGN","BK4539","CRVO","XTIA","BK4555","BK4108","BK4134","IPW","BK4077","BSFC","GTBP","LSDI","BK4104","HIMS","BK4205","BK4007","BK4139","BK4212","FLJ","BK4159","BK4233","FFIE","SCPX","BK4183","BRSH"],"gpt_icon":1},{"id":"2436911106","title":"PTC Therapeutics, Oragenics, GT Biopharma among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2436911106","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436911106?lang=en_us&edition=fundamental","pubTime":"2024-05-20 22:00","pubTimestamp":1716213626,"startTime":"0","endTime":"0","summary":"Gainers: GT Biopharma  +180%. Oragenics  +39%. Dyne Therapeutics DYN +22%. NKGen Biotech  +24%. PTC Therapeutics  +21%.  Losers: Lucy Scientific Discovery  -18%. biote  -10%. Aspira Women's Health  -10%. Compugen CGEN -10%. Flora Growth  -7%.   S&P 500 Health Care Sector -0.1% to 1701.36. Health Care Equipment & Services -0.33% to 1964.79. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.06% to 1398.51.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108343-ptc-therapeutics-oragenics-gt-biopharma-among-healthcare-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4559","BK4007","LU0320765992.SGD","SH","AWH","BK4082","BK4534","BK4023","DYN","FLGC","LU0109394709.USD","BK4505","BK4539","BK4554","BK4183","UPRO","OEX","VOO","GTBP",".SPX","LU1951200564.SGD","GT","BTMD","LU1951198990.SGD","BK4139","LU1923623000.USD","ESmain","LSDI","BK4588","OEF","LU0889565916.HKD","BK4504","PTC","OGEN","PTCT","NKGN","SDS","SPXU","IVV","BK4550","BK4581","SSO","BK4576","SPY","BK4585"],"gpt_icon":0},{"id":"2436106919","title":"GLBE, STRO and GTBP are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2436106919","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436106919?lang=en_us&edition=fundamental","pubTime":"2024-05-20 21:58","pubTimestamp":1716213488,"startTime":"0","endTime":"0","summary":"Gainers: GT Biopharma  +137%. Faraday Future Intelligent Electric  +93% stock revival comes ahead of shift to T+1 settlement.  Crown ElectroKinetics  +59%. Mmtec  +44%. Oragenics  +24%. YY Group Holding  +26%. Overseas Shipholding  +22% Shipholding bought by Saltchuk Resources for $8.50/share.  NKGen Biotech  +22% SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease.  Dyne Therapeutics  +19% announces data from early stage trials of muscular dystrophy treatments.  Jiade  +19%. Global E Online  +19% soars after boosting full-year revenue guidance, narrowing its quarterly loss  PTC Therapeutics  +18% Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation.  Sutro Biopharma  +17%. Greenwave Technology Solutions  +17%. Brand Engagement Network  +15%.","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108341-glbe-stro-and-gtbp-are-among-premarket-gainers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["GWAV","BK4134","BK4220","LU0320765992.SGD","BK4204","BK4144","BK4120","BK4122","CRKN","BK4023","DYN","LU0109394709.USD","BK4505","JDZG","BK4539","GTBP","GLBE","BK4099","BK4139","BK4588","STRO","LU0889565916.HKD","PTCT","OGEN","MTC","BNAI","NKGN","FFIE","BK4090","BK4555","OSG","YYGH","BK4585"],"gpt_icon":1},{"id":"2436105885","title":"BRIEF-Nkgen Biotech’S Snk01 Nk Cell Therapy Cleared To Start Phase 2 Clinical Trial In Alzheimer’S Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2436105885","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436105885?lang=en_us&edition=fundamental","pubTime":"2024-05-20 21:29","pubTimestamp":1716211782,"startTime":"0","endTime":"0","summary":"May 20  - Nkgen Biotech Inc   :   * NKGEN BIOTECH’S SNK01 NK CELL THERAPY CLEARED TO START PHASE 2 CLINICAL TRIAL  IN ALZHEIMER’S DISEASE   * NKGEN BIOTECH INC: ADVANCES SNK01 INTO PHASE 2 IN MODERATE ALZHEIMER'S DISEASE; FIRST PATIENT ENROLLED IN PHASE 2 EXPECTED IN Q2 2024Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2436036071","title":"NKGen Shares Soar After SNK01 Cleared for Phase 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2436036071","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436036071?lang=en_us&edition=fundamental","pubTime":"2024-05-20 21:11","pubTimestamp":1716210660,"startTime":"0","endTime":"0","summary":"Shares of NKGen Biotech jumped after the company was cleared to progress its SNK01 cell product for the treatment of Alzheimer's disease into its next phase of clinical development.The stock was up 28% at $1.43 in premarket trading. Shares had fallen nearly 60% year-to-date when the market closed Friday.The clinical-stage biotechnology company said Monday morning that its safety review committee has cleared the company's cryopreserved autologous, expanded and enhanced SNK01, to move into Phase II clinical trials.In Phase I of the study, 90% of patients demonstrated improvement or maintained stable cognitive function after only four doses of SNK01.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKGN","BK4139"],"gpt_icon":0},{"id":"2436517099","title":"BUZZ-NKGen rises on clearance to start mid-stage study on Alzheimer's therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2436517099","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436517099?lang=en_us&edition=fundamental","pubTime":"2024-05-20 20:35","pubTimestamp":1716208554,"startTime":"0","endTime":"0","summary":"** Shares of drug developer NKGen Biotech    rise 40.2% to $1.58 premarket   ** Co says its safety review committee allowed a start on its mid-stage study on its cell therapy for Alzheimer's disease    ** NKGN expects its first patient to be enrolled in Q2    ** In an early-stage trial, the therapy SNK01 showed improvement or maintained stable cognitive function in 90% of patients   ** Up to last close, stock down 59.3% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKGN","BUZZ","BK4139"],"gpt_icon":0},{"id":"2436172093","title":"NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial  in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2436172093","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436172093?lang=en_us&edition=fundamental","pubTime":"2024-05-20 20:05","pubTimestamp":1716206700,"startTime":"0","endTime":"0","summary":"SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events.Company advances SNK01 into Phase 2 in moderate Alzheimer’s disease; first patient enrolled in Phase 2 expected in Q2 2024.“We are excited to announce another important clinical milestone in our mission to advance SNK01 as the first potential disease modifying treatment of its kind for patients with more advanced Alzheimer’s disease,” said Paul Y. Song, MD, Chairman and CEO of NKGen. “The Phase 2 trial will utilize our cryopreserved SNK01 product given at the highest dose we have ever delivered, and for a full year duration. To date, SNK01 has been found to be well-tol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B1ZPiw9UAepRzBSTCPQGgA--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/ff5a796e664612eddb6f6d9bc19bccdf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B1ZPiw9UAepRzBSTCPQGgA--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/ff5a796e664612eddb6f6d9bc19bccdf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkgen-biotech-snk01-nk-cell-120500094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKGNW","NKGN","BK4139"],"gpt_icon":0},{"id":"2431734289","title":"NKTR, IMNM and MAIA are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431734289","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431734289?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:42","pubTimestamp":1714480935,"startTime":"0","endTime":"0","summary":"Gainers: Cyclacel Pharmaceuticals Inc (CYCC) +60% FORM 10-K/A | Amended Annual Report.  Auddia Inc (AUUD) +34% Announces Strategic Product Expansion With Cloud Based Artificial Intelligence and Natura","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4096200-nktr-imnm-and-maia-are-among-premarket-gainers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BRTX","BK4083","BK4581","LL","IMNM","NKTR","MLEC","BK4023","XFOR","OTLY","BK4527","LU1861220207.SGD","BK7501","LU1267930730.SGD","LU0640476718.USD","LU2602419157.SGD","MMM","MRIN","TENX","BK4524","BK4563","NKGN","MULN","IE00BFTCPJ56.SGD","LU0238689110.USD","WGS","BOF","AUUD","MMM.AU","ADXN","BK7040","LU0820561818.USD","BK4588","PYPL","LU1861217088.USD","LLY","LU0158827948.USD","LTRX","BK4139","BK4212","LU0198837287.USD","LU0456855351.SGD","LU0320765059.SGD","NNVC","LU1064131342.USD","IE00B2B36J28.USD","CYCC","BLND","MAIA","LU0417517546.SGD"],"gpt_icon":0},{"id":"2431852183","title":"NKGen Biotech Shares Rise 15% After FDA Clears Application for Parkinson's Disease Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2431852183","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431852183?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:53","pubTimestamp":1714395180,"startTime":"0","endTime":"0","summary":"NKGen Biotech shares rose after the company said the Food and Drug Administration cleared its investigational new drug application for SNK01 NK cell therapy to treat Parkinson's disease.Shares were up 15% to $1.85 in premarket trading. The stock closed Friday's session down 19%, and was down 84% for the past 12 months at Friday's close.The biotechnology company said the FDA clearance enables it to initiate a Phase 1/2a clinical trial evaluating the safety, tolerability, and exploratory efficacy of SNK01 in patients with Parkinson's.The trial is designed to enroll up to 30 patients, with 20 receiving SNK01 and 10 receiving a placebo. NKGen expects to begin the trial, with the first patient dosed, in the second half of 2024.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKGN","BK4139"],"gpt_icon":0},{"id":"2431854199","title":"PHG, IBRX and MESO are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431854199","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431854199?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:36","pubTimestamp":1714394210,"startTime":"0","endTime":"0","summary":"Gainers: Deciphera Pharmaceuticals  +71%. Koninklijke Philips  +41%. ZyVersa Therapeutics  +36%. HWH International  +16%. NewGenIvf Group  +16%. iClick Interactive Asia Group  +14%. Immunity  +13%. Solowin  +13%. NKGen Biotech  +3% Announces FDA Clearance of Investigational New Drug  Application for SNK01 NK Cell Therapy in Parkinson’s Disease  Fulton Financial  +12% surges after Republic First deal and upgrade at Janney.  Tesla  +11% moment in China helps lift Chinese electric vehicle stocks.  Mesoblast  +9%. WISeKey International  +8% Strengthens Its Strategic Partnership with Swiss Armed Forces in the Space Sector for 2024 and Beyond; Plans Include the Launch of an Enhanced WISeSat Satellite in Q3 2024 Using SpaceX.  Dominos Pizza  +6% rallies after comparable sales growth sizzles in Q1  AGBA Group  +6%. MicroCloud Hologram  +6%. VivoPower International  +6% to sell Kenshaw Electrical  ABVC BioPharma  +6%. WiSA Technologies  +5%. Paramount Global  +5% makes 'best and final' offer fo","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095430-phg-ibrx-and-meso-are-among-premarket-gainers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["DCPH","HOLO","LU2249611893.SGD","LU0173614495.USD","BK4511","LU1551013425.SGD","BK4533","SWIN","IBRX","BK4514","BK4009","NIVF","BK4531","PARA","AGBA","LU2357305700.SGD","NKGN","HWH.AU","HWH","BK4535","ZVSA","WISA","LU1115378108.SGD","PHG","JKS","WKEY","BK4555","BIDU","IE00B1XK9C88.USD","VVPR","LU1551013342.USD","LU0316494557.USD","MESO","DPZ","BK4127","BK4082","FULT","BK4565","IND.AU","BK4209","LU0943347566.SGD","BK4534","HSAI","LU1720051017.SGD","LU0287142896.SGD","LU1914381329.SGD","ICLK","BK4519","ABVC"],"gpt_icon":0},{"id":"2431855087","title":"BRIEF-Nkgen Biotech Expects To Initiate Phase 1 Clinical Trial For PD In 2H2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2431855087","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431855087?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:03","pubTimestamp":1714392218,"startTime":"0","endTime":"0","summary":"April 29  - Nkgen Biotech Inc   :   * NKGEN BIOTECH ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG  APPLICATION FOR SNK01 NK CELL THERAPY IN PARKINSON’S DISEASE   * NKGEN BIOTECH INC: EXPECTS TO INITIATE A PHASE 1 CLINICAL TRIAL IN PD IN 2H 2024.Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4139","PD","NKGN","BK4023","LU1169590202.USD"],"gpt_icon":0},{"id":"2431856674","title":"NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2431856674","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431856674?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:00","pubTimestamp":1714392000,"startTime":"0","endTime":"0","summary":"NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients with Parkinson’s disease.The Company expects to initiate a Phase 1 clinical trial in PD in 2H 2024.Dr. Song further commented, “Given the encouraging outcomes regarding the reduction in neuroinflammation observed in our Phase 1 Alzheimer’s trials, we are optimistic about the potential benefits that may emerge in our Parkinson’s trial. Although these two neurodegenerative diseases differ, both share a neuroinflammatory component, which has led to our hypothesis that SNK01 may be beneficial in both indications. While directly inhibiting neuroinflammation, whether as an independent approach or in conjunction with other interventions, may not address the etiology, it can potentially decrease the production of factors that contribute to neurotoxicity, thereby hopefully leading to clinical improvements.”","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B1ZPiw9UAepRzBSTCPQGgA--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/ff5a796e664612eddb6f6d9bc19bccdf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B1ZPiw9UAepRzBSTCPQGgA--~B/aD04NTY7dz0yOTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/ff5a796e664612eddb6f6d9bc19bccdf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkgen-biotech-announces-fda-clearance-120000042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKGNW","BK4139","NKGN"],"gpt_icon":0},{"id":"2429453590","title":"ING, PALI and FNCH among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2429453590","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2429453590?lang=en_us&edition=fundamental","pubTime":"2024-04-24 20:45","pubTimestamp":1713962723,"startTime":"0","endTime":"0","summary":"Losers: Evotec SE  -31% reports FY results  Finch Therapeutics Group  -14%. NKGen Biotech  -14%. HWH International  -13%. Neo-Concept International Group Holdings Ltd.  -12%. SILO Pharma  -9%. AGBA Group Holding Limited  -9%. Equinox Gold Corp  -8% buys rest of Greenstone gold mine in $995M cash and stock deal.  Enphase Energy  -7% after Q1 earnings release. ING Groep N.V.  -6%. Zhongchao  -6%. Cazoo Group Ltd  -6%. Palisade Bio  -5%.   More on pre-market losers & stocks.  ING: Still Too Cheap Despite Disappointing Results ING Groep NV  Q4 2023 Earnings Call Transcript Palisade Bio stock rallies nearly 100% on colitis drug analysis Palisade Bio stock slides 8% amid colitis drug presentation Financial information for Finch Therapeutics","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4093088-ing-pali-and-fnch-among-pre-market-losers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU2357305700.SGD","ING","BK4017","EVO","HWH","ZCMD","BK7141","BK4121","BK4207","BK4077","ING.AU","BK7505","LU0348723411.USD","LU0082616367.USD","AGBA","BK4122","FNCH","BK4202","CZOO","BK7129","EQX.AU","HWH.AU","BK7132","LU0719512351.SGD","BK4007","LU1720051017.SGD","PALI","EQX","BK4184","BK4588","SILO","BK4214","LU1720051108.HKD","EVO.AU","NCI","NKGN","BK4585","ENPH","BK4139","LU1548497426.USD","BK4204","BK4147"],"gpt_icon":0},{"id":"2429194866","title":"HRTX, MESO and POET are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2429194866","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2429194866?lang=en_us&edition=fundamental","pubTime":"2024-04-23 20:48","pubTimestamp":1713876530,"startTime":"0","endTime":"0","summary":"Gainers: HWH International  +37%. Smart for Life  +32%. NKGen Biotech  +31%. Hibbett  +19% to acquire Hibbett in $1.1B deal  Immunity  +18% stock jumps as FDA clears bladder cancer therapy  SILO Pharma  +26% Announces Positive Results for Intranasal PTSD Treatment  AGBA Group Holding  +15%. Edible Garden  +17% regains compliance with Nasdaq bid price requirement  Oportun Financial  +15% Announces Preliminary Q1 2024 Financial Information  Zhongchao  +13%. Cango  +9% authorizes new $50 million share buyback program  Gorilla Technology Group  +9%. Danaher  +8% gains as Q1 results exceed expectations  POET Technologies  +7%. Wetouch Technology  +7% Technology grows 2024 revenue by 41%  Spotify Technology  +7% rises as premium subscribers grow in Q1, despite lower than expected monthly users  WiSA Technologies  +6%. Mesoblast  +6%. PENN Entertainment  +6% Names Aaron LaBerge Chief Technology Officer  SES AI Corporation  +6% Announces its May 2024 Event Calendar  Heron Therapeutics  +5%. Ki","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4092436-hrtx-meso-and-poet-are-among-premarket-gainers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0390134368.USD","LU1551013342.USD","DHR","BK7017","LU0114720955.EUR","GRRR","BK4200","BK4077","LU0289961442.SGD","LU1917777945.USD","PENN","BK4148","WISA","OPRT","EDBL","NKGN","SMFL","AGBA","HRTX","LU0175139822.USD","LU2265009873.SGD","HIBB","LU0312595415.SGD","POET","WETH","BK4567","LU0943347566.SGD","BK4122","KMB","CANG","BK4571","SES","SILO","LU1804176565.USD","ZCMD","BK4141","IBRX","LU0820561909.HKD","DHR.AU","LU0511384066.AUD","IE00BKVL7J92.USD","LU0097036916.USD","MESO","BK4585","BK4096","LU0689472784.USD","SES.AU","HWH.AU","SPOT","HWH"],"gpt_icon":0},{"id":"2429287979","title":"MRIN, WISA and SMFL among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2429287979","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2429287979?lang=en_us&edition=fundamental","pubTime":"2024-04-23 00:52","pubTimestamp":1713804734,"startTime":"0","endTime":"0","summary":"Gainers: Matterport  +180%. mF International Ltd  +149%. Edible Garden AG  +84%. AGBA Group Holding Limited  +81%. Moolec Science  +64%. NKGen Biotech  +28%. Tungray Technologies Inc Class A Ordinary Shares  +25%. ProKidney Corp  +24%.  Smart for Life  +24%. Captivision  +23%.  Losers: YY Group Holding Limited Class A Ordinary Shares  -30%. Bio-Path Holdings  -30%. Telomir Pharmaceuticals  -27%. Hepion Pharmaceuticals  -26%. Inhibikase Therapeutics  -26%. Top Wealth Group Holding Limited  -24%. WiSA Technologies  -20%. Iczoom Group  -19%. Marin Software  -19%. Redwoods Acquisition Corp  -19%.   More on Mid-day movers & stocks.  Marin Software Incorporated  Q4 2023 Earnings Call Transcript WiSA signs its fifth WiSA E licensing deal with major consumer electronics company WiSA jumps on announcing fourth HDTV/PTV license with major TV brand Financial information for Marin Software  Financial information for Smart for Life","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4092072-mrin-wisa-and-smfl-among-mid-day-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4141","MLEC","RWOD","BK4189","BK4007","AGBA","BK4554","IKT","TELO","BK4023","CAPT","TWG","SMFL","MRIN","IZM","BK4184","BK4086","BK4212","NKGN","YYGH","MFI","EDBL","PROK","BK4140","HEPA","BK4139","MTTR","BK4183","WISA","BPTH","TRSG"],"gpt_icon":0},{"id":"2429928601","title":"OGI, FMS and POET are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2429928601","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2429928601?lang=en_us&edition=fundamental","pubTime":"2024-04-22 20:21","pubTimestamp":1713788508,"startTime":"0","endTime":"0","summary":"Gainers: Moolec Science  +113% achieves USDA approval for plant-grown animal proteins, shares jump.  NKGen Biotech  +37%. AGBA Group Holding  +22%. POET Technologies  +14%. Tungray Technologies  +14%. Syra Health  +10% wins Training Contract from Sedgwick County Health Department in Kansas to Combat Substance Use Disorder.  Gryphon Digital Mining  +9% Announces Stock Repurchase Program; Machine Upgrade Program Completed Ahead of Schedule.  Fresenius Medical Care  +7%. Lytus Technologies  +6%. OrganiGram  +6%. Zapata Computing  +6%. Marti Technologies  +6%. Riot Platforms  +5% INFA, crypto-related stocks and more.  ARB IOT Group  +5%.   More on premarket gainers & stock  Organigram Is My Favorite Cannabis Stock Again Organigram: Operating In A Structurally Challenged Industry Broyhill - Fresenius Medical Care: Correctly Focused On Increasing Margins And Returns Canadian cannabis stocks rally as industry exec. elected to lead lobby group Organigram's SHRED brand surpasses $200M in yearly","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4091859-ogi-fms-and-poet-are-among-premarket-gainers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4212","RIOT","BK4595","BK4007","GRYP","BK4184","NKGN","LYT","POET","BK4141","FMS.AU","BK4196","MLEC","BK4230","TRSG","BK4023","BK7129","FMS","BK4139","ARBB","MRT","OGI","BK4108","AGBA","BK4557","BK4134","ZPTA","SYRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nkgenbiotech.com","stockEarnings":[{"period":"1week","weight":-0.1317},{"period":"1month","weight":0.0741},{"period":"3month","weight":-0.3349},{"period":"6month","weight":-0.5735},{"period":"1year","weight":-0.8589},{"period":"ytd","weight":-0.4727}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0.0325},{"period":"3month","weight":0.0436},{"period":"6month","weight":0.1604},{"period":"1year","weight":0.2444},{"period":"ytd","weight":0.1235}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.14783},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.154196},{"month":3,"riseRate":0.666667,"avgChangeRate":0.457766},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.062968},{"month":5,"riseRate":0.666667,"avgChangeRate":0.034541},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.040277},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003172},{"month":8,"riseRate":0.333333,"avgChangeRate":0.005703},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.068468},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.211203},{"month":11,"riseRate":0.666667,"avgChangeRate":0.061175},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.067297}],"exchange":"NYSE","name":"NKGEN BIOTECH INC","nameEN":"NKGEN BIOTECH INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NKGEN BIOTECH INC(NKGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NKGEN BIOTECH INC(NKGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NKGEN BIOTECH INC,NKGN,NKGEN BIOTECH INC股票,NKGEN BIOTECH INC股票老虎,NKGEN BIOTECH INC股票老虎国际,NKGEN BIOTECH INC行情,NKGEN BIOTECH INC股票行情,NKGEN BIOTECH INC股价,NKGEN BIOTECH INC股市,NKGEN BIOTECH INC股票价格,NKGEN BIOTECH INC股票交易,NKGEN BIOTECH INC股票购买,NKGEN BIOTECH INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NKGEN BIOTECH INC(NKGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NKGEN BIOTECH INC(NKGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction